How much could a $10,000 investment in these undervalued ASX 200 shares be worth in a year?

It has been well documented this year that ASX 200 healthcare and technology shares have struggled. 

Last week, tech shares rallied in what investors will be hoping is a long term rebound. 

Despite the rally, the S&P/ASX 200 Information Technology Index (ASX:XIJ) remains down 17% year to date.

Meanwhile, the S&P/ASX 200 Health Care Index (ASX: XHJ) is down more than 16%. 

For comparison, the S&P/ASX 200 Index (ASX: XJO) is up just over 2%. 

Looking at these sectors, there is a significant opportunity for investors to buy low on quality companies. 

Let’s look at three examples that could bring strong returns if ASX 200 shares return to broker estimates in the next 12 months. 

Pro Medicus Ltd (ASX: PME)

Pro Medicus is one of the largest ASX healthcare stocks by market cap. 

It has fallen significantly over the last year, including 33% year to date. 

However, broker estimates now indicate it is heavily undervalued.

In a note out of Morgans today, the broker updated its price target to $210 per share for this ASX 200 stock. 

From today’s opening price of approximately $146.74, this indicates a potential upside of more than 43%. 

If Pro Medicus shares were to reach that price target in the next 12 months, a $10,000 investment could potentially grow to $14,310. 

CSL Ltd (ASX: CSL)

CSL is another ASX 200 healthcare stock that has been struggling in the last 12 months. 

In 2026 alone, this blue-chip healthcare stock has fallen nearly 20%. 

It has opened trading today at roughly $138 per share. 

However, broker estimates place its fair value at roughly $201.41 per share. 

That’s a 46% upside potential. 

If a $10,000 investment reached that target in the next 12 months, investors would be enjoying a $4,600, for a total value of $14,600. 

The Motley Fool’s Grace Alvino also investigated the upside potential of CSL shares should they return to previous highs. 

Back in 2020, CSL shares peaked at $342.75 per share. 

Her estimates show that a $10,000 investment could more than double should they ever reach that level again. 

WiseTech Global Ltd (ASX: WTC)

WiseTech shares have been one of the hardest hit technology shares this year. 

However they have enjoyed a rebound over the last week. 

The company is a provider of logistics software that aims to improve the world’s supply chains, however has suffered due to AI disruption fears. 

Due to this negative sentiment, WiseTech shares are down 33% year to date. 

If these tech shares can rally to consensus targets of $78.30, a $10,000 investment would reach just over $17,000 in the next 12 months. 

The post How much could a $10,000 investment in these undervalued ASX 200 shares be worth in a year? appeared first on The Motley Fool Australia.

More reading

• Why did Morgans just lower its outlook on Collins Food and Pro Medicus shares?
• This ASX shares and ETF mix could be the key to early retirement
• 3 under-the-radar ASX AI shares that could be the next WiseTech
• If I had $10,000, this is the ASX stock I’d buy right now
• How to build a $500,000 ASX share portfolio step by step

Motley Fool contributor Aaron Bell has positions in WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.